Paper Details

  1. Home
  2. Paper Details

[Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].

Author: AkataniRitsu, ChiharaNorio, KatanazakaKimitaka, MatsumotoRiki, SekiguchiKenji, UedaTakehiro

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study describes a case of a woman with multiple sclerosis (MS) who experienced worsening of her symptoms after switching from one disease-modifying therapy to another.
Paper Details　
Original Abstract of the Article :
A 42-year-old woman diagnosed with multiple sclerosis (MS) at the age of 37 was initially treated with interferon-β IM. The frequency of clinical relapses was twice in 4 years. At the age of 41, due to difficulty in administering muscle injections, an oral medication fingolimod was started. How...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.5692/clinicalneurol.cn-001307

データ提供：米国国立医学図書館（NLM）

Navigating the Complexities of Multiple Sclerosis Treatment

Multiple sclerosis (MS) is a complex and challenging neurological disease. This case report highlights the potential for disease activity exacerbation when switching between disease-modifying therapies (DMTs). The researchers describe a patient who experienced an increase in relapses and MRI lesions after switching from fingolimod to natalizumab.

The Rebound Effect: A Potential Challenge in MS Treatment

The case report suggests a possible link between the cessation of fingolimod and the subsequent increase in disease activity, potentially due to a rebound syndrome. Additionally, the presence of anti-natalizumab antibodies may have contributed to the exacerbation of disease activity.

Personalized Approaches: Tailoring MS Treatment

This case report underscores the importance of individualized treatment approaches for MS patients. Careful monitoring and consideration of potential risks and benefits are essential when switching DMTs. Think of it as a camel caravan adjusting its route and pace based on the changing terrain of the desert, adapting to the unique needs of each individual.

Dr. Camel's Conclusion

This case report provides a valuable reminder of the complex nature of MS treatment. It highlights the potential for disease activity exacerbation when switching DMTs and underscores the importance of individualized treatment plans and close monitoring of patients.

Date :
  1. Date Completed 2019-12-16
  2. Date Revised 2019-12-17
Further Info :

Pubmed ID

31341130

DOI: Digital Object Identifier

10.5692/clinicalneurol.cn-001307

Related Literature

Article Analysis
・Effects of natalizumab injection
SNS
PICO Info
in preparation
Languages

Japanese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.